Catalyst Event
Merck and Co Inc (MRK) · Earnings Release
From KEDI Global Obesity Care Industry Top 2+ Index (OBCI)
4/30/2026, 12:00:00 AM
Reported Q1 2026 financial results, posting a GAAP Loss per Share of $1.72, which included a $3.62 per share charge from the acquisition of Cidara Therapeutics. Revenue grew 5% to $16.3 billion. The company raised its full-year 2026 guidance; high importance due to guidance raise and acquisition impact, market reaction expected.
Korean Translation
2026년 1분기 재무 실적 발표, Cidara Therapeutics 인수 관련 주당 3.62달러의 비용을 포함하여 주당순손실(GAAP) 1.72달러를 기록함. 매출은 163억 달러로 5% 증가했으며, 2026년 연간 가이던스를 상향 조정함. 가이던스 상향 및 인수 영향에 따른 높은 중요도로 시장 반응 예상됨.
Related Recent Events
DICK'S Sporting Goods Inc (DKS) · Earnings Release
Q1 2026 earnings release is scheduled for 2026-05-27. Medium importance estimated as earnings releases for high-growth companies typically result in ≥5% price movement. Analysts forecast EPS of approximately $2.93 forecasted.
5/27/2026, 12:00:00 AM
Novo Nordisk A/S (NVO) · Earnings Release
High importance estimated as earnings releases for major pharma often result in >10% price movement. Q1 2026 earnings release scheduled. Analysts forecast EPS of $0.87 and revenue of $11.35 billion forecasted.
5/6/2026, 12:00:00 AM
Eli Lilly and Co (LLY) · Earnings Release
Eli Lilly reported Q1 2026 revenue of $19.8 billion (+56% YoY) and non-GAAP EPS of $8.55, beating estimates. The company raised its full-year 2026 revenue guidance to $82-$85 billion, driven by strong sales of Mounjaro and Zepbound. This significant growth and guidance raise is estimated to result in a >10% price impact.
4/30/2026, 12:00:00 AM
Eli Lilly and Co (LLY) · Other
The U.S. FDA proposed removing tirzepatide, the active ingredient in Mounjaro and Zepbound, from the bulk drug substances list on 2026-04-30, restricting compounded versions. This regulatory protection of market share is estimated to result in a >10% price impact.
4/30/2026, 12:00:00 AM
Novo Nordisk A/S (NVO) · Other
High importance estimated as this regulatory change protects core revenue from competition, likely impacting price by >10%. The U.S. FDA proposed to exclude the active ingredients in key Novo Nordisk GLP-1 drugs from the bulk compounding list.
4/30/2026, 12:00:00 AM
Amgen Inc (AMGN) · Earnings Release
Amgen reported Q1 2026 results on April 30, 2026, with EPS beating analyst forecasts and revenue meeting expectations. This is expected to have a medium market impact (>=5%) due to strong financial performance and a guidance raise, expected.
4/30/2026, 12:00:00 AM